Skip to main
TERN

Terns Pharmaceuticals (TERN) Stock Forecast & Price Target

Terns Pharmaceuticals (TERN) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Terns Pharmaceuticals Inc. has enhanced its probability of success for its lead product candidate, TERN-701, increasing it from 40% to 60% due to a compelling data profile that promises earlier and broader adoption. The company's strong financial position, with capital support extending into 2028, combined with multiple upcoming catalysts and clinical differentiation, signifies a promising horizon for potential re-rating in stock value. Additionally, the company boasts a robust intellectual property portfolio with protections lasting until at least 2039, further strengthening the outlook for long-term value creation.

Bears say

Terns Pharmaceuticals Inc faces significant challenges that contribute to a negative outlook on its stock. Key risks include the potential failure of ongoing and future clinical trials, delays in regulatory approvals, and the possibility of unforeseen safety concerns, which could adversely affect the company's product pipeline and resulting market opportunities. Additionally, financial pressures, such as cash requirements and the risk of dilution, further compound these issues, presenting substantial hurdles to achieving the company's strategic objectives.

Terns Pharmaceuticals (TERN) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Terns Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Terns Pharmaceuticals (TERN) Forecast

Analysts have given Terns Pharmaceuticals (TERN) a Buy based on their latest research and market trends.

According to 9 analysts, Terns Pharmaceuticals (TERN) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Terns Pharmaceuticals (TERN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.